Heart failure & cardiomyopathies
Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
Authors' conclusion
Aficamten resulted in sustained improvements across multiple health status dimensions, which also correlated with clinical markers of oHCM severity.
Study context
- Population
- Participants with obstructive hypertrophic cardiomyopathy (oHCM) completing an aficamten trialcompleted 48 weeks
- Participants
- 172 participants
- Outcome
- Change from baseline in PROs (KCCQ-OSS, S-Summary, EQ-5D-5L index, VAS) with aficamten
- Follow-up
- 48 weeks
Main finding
As reported in the abstract
- KCCQ-OSS mean improvement, points (16.9-20.6), P < 0.001
- 18.8
- Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life domain improvement, points (23.2-28.5; P < 0.001)
- 25.8
- S-Summary Score increase (15.1-19.4; p < 0.001)
- 17.2
- EQ-5D-5L index improvement (p < 0.001)
- 0.11
- Visual analogue scale (VAS) improvement, points (p < 0.001)
- 12.7
Further findings
Correlation of PRO improvements with clinical measures of oHCM
- Improvements in patient-reported outcomes (PROs) significantly correlated with important clinical measures of oHCM
Original publication
Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM. Eur J Heart Fail. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →